Coronavirus disease 2019 in Latin American patients with multiple sclerosis

AbstractPatients with multiple sclerosis (MS) who present coronavirus disease 2019 (COVID-19) are of particular interest to neurologists. These patients have a neuroimmune disease and receive immunomodulatory or immunosuppressive therapies in the long-term. We present here data from 73 patients with...

Full description

Saved in:
Bibliographic Details
Published in:Multiple sclerosis and related disorders 2021-10, Vol.55, p.103173-103173, Article 103173
Main Authors: Fragoso, Yara D, Schiavetti, Irene, Carmisciano, Luca, Ponzano, Marta, Steinberg, Judith, Treviño-Frenk, Irene, Ciampi, Ethel, Vecino, Maria Cecilia A, Correa, Edgar P, Carcamo, Claudia, Gomes, Sidney, Pimentel, Maria Lucia V, Santos, Gutemberg A.C, Vrech, Carlos, Winckler, Thereza C.A, Sormani, Maria Pia
Format: Article
Language:English
Subjects:
COVID-19
Multiple sclerosis
Neurology
ocrelizumab
Pandemic
rituximab
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:AbstractPatients with multiple sclerosis (MS) who present coronavirus disease 2019 (COVID-19) are of particular interest to neurologists. These patients have a neuroimmune disease and receive immunomodulatory or immunosuppressive therapies in the long-term. We present here data from 73 patients with MS and a confirmed diagnosis of COVID-19 from five Latin American countries. Fifteen patients (20.5%) were hospitalized and two patients died. The use of anti-CD20 therapies was the only risk factor associated to hospitalization and death. Despite the small sample size, this study highlights the awareness regarding therapeutic options for MS during the pandemic.
ISSN:2211-0348
2211-0356
DOI:10.1016/j.msard.2021.103173